Lv0
0 积分 2022-08-30 加入
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
12小时前
已完结
Moving towards personalized treatments of immune-related adverse events
13小时前
已完结
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
4天前
已完结
RB functions as a key regulator of senescence and tumor suppression
4天前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
16天前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
18天前
已完结
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
20天前
已关闭
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
1个月前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
1个月前
已完结
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
1个月前
已完结
皖公网安备34019202002308
